ESTRO 2024 - Abstract Book

S1999

Clinical - Mixed sites, palliation

ESTRO 2024

Keywords: SABR, MR-guided, toxicity

References:

[1] Diez P, Hanna GG, Aitken KL, et al. UK 2022 Consensus on Normal Tissue Dose-Volume Constraints for Oligometastatic, Primary Lung and Hepatocellular Carcinoma Stereotactic Ablative Radiotherapy. Clin Oncol (R Coll Radiol). 2022;34:288-300. https://doi.org/10.1016/j.clon.2022.02.010.

[2] Grimm J, Marks LB, Jackson A, et al. High Dose per Fraction, Hypofractionated Treatment Effects in the Clinic (HyTEC): An Overview. Int J Radiat Oncol Biol Phys. 2021;110:1-10. https://doi.org/10.1016/j.ijrobp.2020.10.039.

[3] Benedict SH, Yenice KM, Followill D, et al. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys. 2010;37:4078-101. https://doi.org/10.1118/1.3438081.

[4] Bentzen SM, Vogelius IR. Using and Understanding Survival Statistics - or How We Learned to Stop Worrying and Love the Kaplan-Meier Estimate. Int J Radiat Oncol Biol Phys. 2023;115:839-46. https://doi.org/10.1016/j.ijrobp.2022.11.035.

2932

Digital Poster

Oligometastatic liver SABR: clinical outcomes and evaluation of relapse pattern

Lauren Jones, Calvin Lee Man Ho, Luis Aznar-Garcia

Nottingham University Hospitals, Clinical Oncology, Nottingham, United Kingdom

Purpose/Objective:

To assess clinical outcomes of 45 patients treated with SABR for liver oligometastases at a single UK centre between 2016 - 2022 and to assess relapse pattern in those who developed local disease progression post-SABR to ascertain whether relapse was within an ablative dose volume.

Material/Methods:

Demographics and baseline metastasis characteristics including size and primary tumour histology were collected for each patient. Radiological response to SABR was assessed with CT/MRI imaging with best radiological response to SABR and time to best radiological response recorded. Patients who developed local tumour progression of the treated liver metastasis had retrospective dosimetric assessment performed; to facilitate this, post-SABR diagnostic quality imaging confirming disease progression was fused with SABR radiotherapy planning CT scan to ascertain whether site of relapse was within an ablative dose volume.